Your search history is turned on.
Date: May 10, 2022 Jurisdictions: British Columbia
completed amendment for name change.pdf ...
Date: August 31, 2017 Jurisdictions: British Columbia
Filed by Avantafile.com - Eternelle Skincare Products Inc. - Form 10-12g/a UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10/A (Amendment No. 1) GENERAL FORM FOR REGISTRATION OF SECURITIES Pursuant to Section 12(b) or (g) of The Securities Exchange Act of 1934 ETERNELLE SKINCARE PRODUCTS INC. (Exact name ...
Date: August 11, 2017 Jurisdictions: British Columbia
!"##$ %&#'$"()*$(+*$,-% %&'#'% .&-!"+% &#$,/ 0 %1!2! 3453/ ...
Date: June 26, 2017 Jurisdictions: British Columbia
!"##$ %&#'$"()*$(+*$,-% %&'#'% .&-!"+% &#$,/ #%"%00% 1'"&!%$2&# "& %3!2! 4564/ ...
Date: January 8, 2015 Jurisdictions: British Columbia
http://www.avantafile.com/bzclient/peptide/form8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 5, 2015 Commission File Number 000-53230 PEPTIDE TECHNOLOGIES, INC. (Exact name of registrant as specified in...
Date: October 20, 2014 Jurisdictions: British Columbia
EXHIBIT 31.2 CERTIFICATION PURSUANT TO 18 U.S.C. ss. 1350, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Baxter Koehn, certify that: 1. I have reviewed this quarterly report on Form 10-Q of PEPTIDE TECHNOLOGIES, INC. 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the s...
EXHIBIT 31.1 CERTIFICATION PURSUANT TO 18 U.S.C. ss. 1350, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Dennis Cox, certify that: 1. I have reviewed this quarterly report on Form 10-Q of PEPTIDE TECHNOLOGIES, INC. 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statemen...
1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended 31 August 2014 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ...
F-3 PART I - FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS PEPTIDE TECHNOLOGIES, INC. (A Development Stage Company) INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Expressed in U.S. Dollars) (Unaudited) AUGUST 31, 2014 Financial Statements Page Interim Consolidated Balance Sheets F-5 Interim Consolidated Statements of Loss and Comprehensive Loss F...